- 產(chǎn)品描述
Quality Control多項違禁品質(zhì)控檢測
廣州健侖生物科技?有限公司
本司長期供應(yīng)尼古?。商鎸帲z測試劑盒,其主要品牌包括美國NovaBios、廣州健侖、廣州創(chuàng)侖等進口產(chǎn)品,國產(chǎn)產(chǎn)品,試劑盒的實驗方法是膠體金方法。
規(guī)格:3瓶/盒 10ml/瓶
濃度:3個梯度
保質(zhì)期:兩年
【什么是質(zhì)控品】
1. 質(zhì)控品的來源:
質(zhì)控品的來源同校準(zhǔn)品大致相同,廠商可能會更具自己的要求添加了很多物質(zhì),此時有些物質(zhì)的添加量常常達(dá)到病理狀態(tài)的高濃度,在應(yīng)用于某一項目時,對這個項目來說基質(zhì)效應(yīng)將更大。
2. 定值方法:
有些廠商會給自己的標(biāo)準(zhǔn)品定一個定值范圍,這個定值范圍是由廠商聯(lián)合幾家使用同樣檢測系統(tǒng)的臨床用戶,僅多次測定得出的均值。此時如果將該質(zhì)控品應(yīng)用于另一個檢測系統(tǒng),由于方法學(xué)的不同,可能得出同廠商給出值有較大差異的值。此時不能認(rèn)為該檢測系統(tǒng)的準(zhǔn)確度不佳。此時需要強調(diào)的是檢測系統(tǒng)都是用來測定新鮮血清的,不是用來測定質(zhì)控品或其他物質(zhì)的。檢測系統(tǒng)只有在檢測新鮮血清是得出的結(jié)果才具有溯源性。不同檢測系統(tǒng)之間只有在檢測新鮮血清時才具可比性。
我司還提供其它進口或國產(chǎn)試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
Quality Control多項違禁品質(zhì)控檢測
歡迎咨詢
歡迎咨詢
以下是出售的一小部分產(chǎn)品
名稱 | 英文名 | 尿檢為陽性的時間段(用藥后),僅供參考 | 備注 |
MOP | Morphine, the main component of heroin | 2小時-4天 | A variety of drugs can be detected in time will be positive individual differences, the metabolic rate and detection results and taking individual, route of Administration (suction, oral, injection) and each dosage has a great relationship. In general, the metabolism of injection speed, quickly urine can be positive, other treatment methods is relatively slow. A large amount of urine test lasted for a long time |
MAMP | Morphine / methamphetamine | 1小時-3天 | |
MDMA | Two, two methoxy amphetamine, commonly known as "ecstasy"" | 1小時-5小時 | |
KET | Ketamine (k) | 2小時-4小時 | |
AMP | Amphetamine, also called benzene acetone | 2小時-1天 | |
COC | Cocaine, also called cocaine | 4小時-1天 | |
BZO | Benzene, two nitrogen Zhuo (diazepam, three Lun Lun, etc.) | 2小時-3天 | |
THC | hemp | 2小時-56小時 | |
BAR | Barbiturates | 4小時-4天 | |
MTD | Methadone | 2小時-2天 | |
PCP | Benzene ring piperidine, commonly known as "angel powder. | 2小時-12小時 | |
TCA | Tricyclic antidepressants | 4小時-5天 | |
BUP | Buprenorphine | 1小時-5天 |
二維碼掃一掃
【公司名稱】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化宣傳】
世紀(jì)初,人們發(fā)現(xiàn)在不同種屬或同種不同個體間進行正常組織或腫瘤時出現(xiàn)的排斥反應(yīng)是由細(xì)胞表面主要組織相容性分子(MHC Ⅰ/Ⅱ類分子)決定的。此后,人們又注意到 T 細(xì)胞識別抗原時,存在 MHC 的限制性即 T 細(xì)胞抗原受體 (TCR) 在識別異己抗原時,同時識別自身 MHC 分子。人們對白細(xì)胞分化抗原 (CD) 的大量研究,揭示了 T 細(xì)胞亞群的功能、細(xì)胞激活途經(jīng)和膜信號的轉(zhuǎn)導(dǎo)及細(xì)胞分化過程中的調(diào)控等機制。此外,在研究細(xì)胞毒性T 細(xì)胞(CTL)殺傷作用時,發(fā)現(xiàn) CTL 表達(dá)的 FasL 可與靶細(xì)胞表達(dá)的 Fas 結(jié)合,引起靶細(xì)胞內(nèi)半胱天冬蛋白酶(cassase)級聯(lián)活化,裂解 DNA ,導(dǎo)致靶細(xì)胞死亡稱為細(xì)胞程序性死亡(CD)或細(xì)胞凋亡(aotosis)。六、應(yīng)用免疫學(xué)的發(fā)展 年 Kohler 和 Milstein *雜交瘤技術(shù)。他們將小鼠骨髓瘤細(xì)胞和經(jīng)綿羊紅細(xì)胞(SRBC)致敏的 B 細(xì)胞在體外進行融合形成雜交瘤(hybridoma)。這種雜交瘤細(xì)胞既保持了骨髓瘤細(xì)胞大量無限制生長繁殖的特性,又具有合成和分泌抗體的能力。應(yīng)用該技術(shù)可產(chǎn)生均一的、只針對單一抗原決定基的抗體,稱為單克隆抗體(McAb)。McAb 具有純度高、特異性強、可大量生產(chǎn)等優(yōu)點,已被廣泛應(yīng)用于血清學(xué)診斷、免疫細(xì)胞及其它組織細(xì)胞表面分子的檢測,并通過與核素、各種毒素或藥物化學(xué)偶聯(lián)進行腫瘤導(dǎo)向治療研究。
At the turn of the century, it was discovered that rejection of normal tissues or tumors between different species or individuals of the same species is determined by the major histocompatibility molecules (MHC class I/II molecules) on the cell surface. Since then, people have noticed that when T cells recognize antigens, there is a restriction of MHC, that is, the T cell antigen receptor (TCR) recognizes its own MHC molecules at the same time when it recognizes heterophil antigens. A large number of studies on leukocyte differentiation antigens (CDs) have revealed the function of T cell subsets, cell activation pathways, and transduction of membrane signals, and regulation during cell differentiation. In addition, when studying the killing effect of cytotoxic T cells (CTLs), it was found that FasL expressed by CTLs can bind to Fas expressed by target cells, causing activation of the caspase cascade in target cells, cleaving DNA, and causing targets. Cell death is called programmed cell death (CD) or aotosis. Sixth, the development of applied immunology Kohler and Milstein first hybridoma technology. They fused mouse myeloma cells and sheep erythrocyte (SRBC)-sensitized B cells in vitro to form a hybridoma. This hybridoma cell not only maintains the unrestricted growth and reproduction characteristics of myeloma cells, but also has the ability to synthesize and secrete antibodies. The use of this technique produces a uniform antibody that targets only a single epitope, called a monoclonal antibody (McAb). McAb has the advantages of high purity, specificity, and mass production. It has been widely used in serological diagnosis, detection of cell surface molecules in immune cells and other tissues, and chemical coupling with nuclide, various toxins or drugs. Tumor-oriented treatment research.